10/16/2020 10:32:01 AM
Kazia Executes Deal To Commence GBM Agile Pivotal Study
9/22/2020 10:07:23 AM
Kazia Reaches Clinical Collaboration With Dana-farber Cancer Institute For Primary CNS Lymphoma
8/23/2020 8:55:04 PM
FDA Awards Orphan Drug Designation To Paxalisib For Malignant Glioma, Including DIPG
8/20/2020 10:32:04 AM
Kazia : FDA Awards Fast Track Designation To Paxalisib For Glioblastoma
8/7/2020 10:32:29 AM
Kazia Therapeutics : FDA Grants Rare Pediatric Disease Designation To Paxalisib For DIPG
6/1/2020 10:31:23 AM
Kazia Presents Interim Paxalisib Phase II Data At ASCO Showing Positive Overall Survival Signal
4/7/2020 8:10:26 AM
Kazia's Paxalisib Shows Positive Overall Survival Signal In Phase II Glioblastoma Study
5/20/2019 8:06:48 AM
Kazia Enters Clinical Collaboration For Metastatic Brain Cancer With Alliance For Clinical Trials In Oncology
5/8/2019 10:56:27 PM
Kazia Therapeutics Announces New Positive Data From Phase IIa Trial In Brain Cancer Patients
3/25/2019 1:26:22 AM
Kazia Therapeutics To Present Data From Phase I Study Of Cantrixil In Ovarian Cancer At AACR Annual Meeting